Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy

<b>Background</b>: Invasive and non-invasive pneumococcal diseases are significant health and economic burdens, especially in children and the elderly. Italy included the 7-valent (PCV7) and 13-valent pneumococcal conjugate vaccine (PCV13) in the National Immunization Program in 2007 and...

Full description

Bibliographic Details
Main Authors: Filippo Ansaldi, Sarah Pugh, Daniela Amicizia, Roberto Di Virgilio, Cecilia Trucchi, Andrea Orsi, Alessandro Zollo, Giancarlo Icardi
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Pathogens
Subjects:
cost-effectiveness analysis
impact
pneumococcal infections
pneumococcal vaccines
Online Access:https://www.mdpi.com/2076-0817/9/2/76

Internet

https://www.mdpi.com/2076-0817/9/2/76

Similar Items